Search
for
Sort by
Research 91–120 of 1000+
- Androgen action on human skin – from basic research to clinical significance
- Short-Chain Fatty Acids from <i>Cutibacterium acnes</i> Activate Both a Canonical and Epigenetic Inflammatory Response in Human Sebocytes
- The Role of Oral Contraceptives in the Treatment of Hyperandrogenic Disorders
- Targeting Cutaneous Cannabinoid Signaling in Inflammation - A “High”-way to Heal?
- Synthesis of phenanthridin-3-one derivatives: Non-steroidal inhibitors of steroid 5-α-reductase
- Patients with bullous skin disease in a high‐epidemic COVID‐19 area, Bergamo, Italy
- The Role of Cytochrome P-450 in Dermatology
- FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
- The Therapeutic Potential of Cannabidiol in Skin Conditions
- When bugs and drugs conspire: driving acneiform skin toxicity
- Female Antiandrogens
- Treatment guidelines in adult women
- The Role of Linoleic Acid in Skin and Hair Health: A Review
- The Non-Cosmetic Dermatological Use of Botulinum Neurotoxin
- Antiandrogen Therapy for Skin and Hair Disease
- Use of spironolactone in dermatology.
- ผลของสารสกัดเปลือกมังคุดต่อเชื้อ Propionibacterium acnes
- Androgen Biosynthesis Inhibitors and Androgen Receptor Antagonists
- Лечебный эффект спиронолактона при синдроме гиперандрогении
- 5α‐Reductase inhibitors and prostatic disease
- Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series
- Hospitalists for the NHS
- Is there a ‘gut–brain–skin axis’?
- Cosmetic potential of Southeast Asian herbs: an overview
- Molecular interactions of natural and synthetic steroids in female hamsters’ flank organs
- Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries
- Androgenic disorders of women: Diagnostic and therapeutic decision making
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- Upadacitinib for Severe Alopecia Areata in Adults and Adolescents
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials